Global

Is a more "light-touch" appraisal process the key to getting the UK's NICE to do more with less? Leela Barham reports.

European pharma is bracing itself for EFPIA’s June deadline requiring the disclosure of transfer-of-value transactions make to HCPs. Pharm Exec looks at how the industry is preparing for this historic moment.

The dilemma continues: Which medicines should Europe's health systems pay for – and how much should they pay?

As companies look to raise capital, selling and then leasing back real estate is a tempting option and one that other industries are utilizing, writes Karen Williamson.

while France remains a global force in the pharmaceutical, medical device, and vaccines fields-and continues to tout a solid manufacturing base and re-exportation culture-questions are arising over the long- term sustainability of the country’s healthcare system and its traditionally generous public health provisions.

Reflector sees both altruism and self-interest in European thinking on neglected diseases.

Egypt is not just a sun-soaked paradise defined by pyramids and tombs, or-alternatively-a hotbed for political turmoil and revolution. It’s also a vibrant and growing market for pharmaceuticals, experts contend.

Deep in the massive bureaucracy of the United Nations is an undertaking that appears to have been conceived and designed to be combative - and biopharma may be the target. Stephen Tepp reports.

March 21, 2016

NICE's notion to charge the industry for its technology appraisals looks set to become reality, writes Leela Barham.

Elvis Pacela asks why the prospect of harmonized content is so challenging, and what can pharma companies learn from other sectors about more optimal, modern ways of working and sharing data?

A new wave of technologies supported by innovative business models is transforming the vaccine landscape - and raising the bar on performance. As the demand for cures for chronic diseases accelerates, and with more global outbreaks of viral diseases like Zika and Ebola a virtual certainty, solutions can’t come soon enough.

A new study spells out the many drug pricing problems in Europe just fine, but fails to address a central access issue-leaving its recommendations frustratingly limited for industry and policymakers.

Bruno Villetelle discusses how Japanese companies like Takeda have begun to digitize in order to care for the country's aging population.

The Dutch healthcare system, dubbed today as a “laboratory for change,” is in the midst of reinventing itself around collaborations with industry and government in such areas as market and patient access, transparency, cost-effectiveness, and process innovation.

As a European politician attacks abuses of the orphan drug scheme, a European report extols its virtues. Reflector asks: in Europe, does the right hand know what the left hand is doing?

Arvind Mani and Sherry O' Quinn outline the prevalence of private payer PLAs in Canada.

Following the consultation on the future of England's Cancer Drug Fund, Leela Barham reviews what the stakeholders are thinking.

Whatever used to be wrong with the world of big Pharma could be fixed with a single tag phrase: emerging country markets. Most of the majors have invested heavily in this geographic segment, and the biggest of the big-companies like Novartis-now rely on it for more than a quarter of their global sales. Like all good things, however, there are shadows amidst the sunlight, and the task of turning volume sales into sustainable profits is getting harder.

What the drug industry stands to gain - or lose - from the unthinkable: Britain departing the European Union.

Pharm Exec interviews Subhanu Saxena, CEO of India pharma giant Cipla, who discusses the longtime emerging market champion’s strategic plans to raise its geographic profile and secure the company’s future in the US.

In tandem with South Africa’s institutional advancements, driven by sweeping social and macroeconomic reforms, the pharma industry in the region is capitalizing on its core fundamentals: rising consumer disposable income, a positive demographic profile linked to an aging population, and a diverse disease burden requiring novel cures and treatments.

It’s easy to foresee controversy in 2016 as lagging global economic growth and a messy US political slugfest force the pharma industry’s feet to the fire. Can the industry reclaim a semblance of public approval by confronting its pricing demons and focusing on innovation and a fresh, patient-first message?

Julian Upton sits down with Subhanu Saxena for an update on Cipla's plans to leverage its historic visibility as an emerging market champion to the next level of global leadership in biopharma.

It's an obvious question for every pharmaceutical executive - and the question no-one dares to answer: what happens if the UK leaves the EU?

Kevin E. Noonan asks, what do the biosimilars provisions of the Trans-Pacific Partnership portend for global biologic drug development?

The changing tides in the global healthcare market are showing no signs of letting up. Here's my take on the opportunities, threats, and other big issues facing the industry in the new year.

Telling signs from U.S., Russia, Latin America and UK indicate that governments are squeezing as much value as possible out of their spending on pills and procedures.

Will the UK learn from past efforts to champion innovation in the NHS? Leela Barham assesses the Phase 1 evaluation of its Innovation, Health and Wealth initiative.

Gülce Belgin and Donald Macarthur explore the options available for companies to meet the needs of the rare disease population in Turkey.